Will Alnylam's Vutrisiran receive FDA approval for ATTR-CM by end of 2024? | Binary | | | 4 months ago | |
In how many new countries will Attruby be launched by December 31, 2025? | Categorical | | | 1 month ago | |
Will BridgeBio receive additional FDA approval for Attruby by December 31, 2025? | Binary | | | 1 month ago | |
Will BridgeBio announce a partnership for Attruby distribution by March 31, 2025? | Binary | | | 1 month ago | |
Will BridgeBio's stock price increase by at least 10% by November 30, 2024? | Binary | | | 1 month ago | |
Will BridgeBio's infigratinib complete Phase 3 clinical trials successfully by June 30, 2025? | Binary | | | 3 months ago | |
Will BridgeBio's stock price ($BBIO) remain above $40 by December 31, 2024? | Binary | | | 3 months ago | |
Will the FDA grant full approval for BridgeBio's infigratinib by September 30, 2025? | Binary | | | 3 months ago | |
What will BridgeBio's stock price ($BBIO) be by December 31, 2024? | Categorical | | | 3 months ago | |
Will Alnylam's stock price recover to pre-HELIOS-B Phase 3 study announcement levels by end of 2024? | Binary | | | 4 months ago | |
Will BridgeBio's Acoramidis receive FDA approval for ATTR-CM by end of 2024? | Binary | | | 4 months ago | |
Will Alnylam's stock ($ALNY) reach $250 by the end of 2024? | Binary | | | 4 months ago | |
Will BridgeBio's stock ($BBIO) experience a 20% increase by the end of 2024? | Binary | | | 4 months ago | |
What will be Attruby's market share in ATTR-CM treatment by December 31, 2025? | Categorical | | | 1 month ago | |
What will be BridgeBio's revenue from Attruby sales in 2025? | Categorical | | | 1 month ago | |
Where will BridgeBio's infigratinib be approved by September 30, 2025? | Categorical | | | 3 months ago | |
What will be the status of BridgeBio by September 30, 2025? | Categorical | | | 3 months ago | |
Which drug will show superior primary endpoint results in future clinical trials: Vutrisiran or Acoramidis? | Categorical | | | 4 months ago | |
What will be Alnylam's Vutrisiran sales by end of 2025? | Categorical | | | 4 months ago | |
Which drug will lead the market share in 2025: Vutrisiran or Acoramidis? | Categorical | | | 4 months ago | |
What will be Alnylam's stock ($ALNY) price by the end of 2024? | Categorical | | | 4 months ago | |
Will Alnylam's Vutrisiran (Amvuttra) receive FDA approval for ATTR cardiomyopathy by the end of 2024? | Binary | | | 4 months ago | |
What will be Alnylam's Vutrisiran (Amvuttra) market share in ATTR cardiomyopathy treatments by the end of 2024? | Categorical | | | 4 months ago | |
What will be the next major announcement regarding Vutrisiran (Amvuttra) by the end of 2024? | Categorical | | | 4 months ago | |
